STD Tests: 2026 AI Market Discovery Index

Answer Capsule

In the at-home STD tests category for June 2026, AI systems are concentrating recommendation power around a small set of brands. Nurx leads with the highest AI Authority Value at $2.80M, capturing 15% of the total modeled opportunity. Everlywell ranks second with $936.5K in authority value and the highest raw visibility in the category. Several well-known testing brands appear frequently in AI responses but rarely receive ranked recommendations, creating a clear and commercially significant gap between presence and shortlist eligibility.

Executive Summary

AI platforms are reshaping how consumers discover and choose at-home STD testing services, and the recommendation pattern is already concentrated. Nurx leads the category with a monthly AI Authority Value of $2.80M, capturing 15% of the total $18.67M modeled opportunity. That lead is built on ranking performance, not just frequency: Nurx achieves top-1 recommendation rates of 5.9% on ChatGPT and 8.2% on Perplexity, and its average recommended rank of 1.83 is the strongest across all tracked brands.

Everlywell holds second position with $936.5K in authority value and appears in 62.9% of all AI responses, the highest presence rate in the category. Yet its valid recommendation coverage sits at only 13.7%, a gap that illustrates the core dynamic of this market. High visibility does not produce proportional recommendation outcomes. LetsGetChecked follows with $337.5K in authority value and a 10.9% recommendation coverage, showing consistent but not dominant performance across platforms.

The most commercially significant pattern in this dataset is the disconnect between appearance and advancement. Several brands with established consumer recognition, including myLAB Box, STDcheck.com, and QuestDirect, appear in AI responses at meaningful rates but generate little or no ranked recommendation credit. This gap is not a visibility problem. It is a recommendation architecture problem, and it has direct consequences for AI-driven buyer discovery.

The AI Discovery Shift in STD Tests

When a buyer asks an AI platform which at-home STD test to order, the response functions as a shortlist. The brands that appear in ranked positions gain a structural commercial advantage. The brands that are mentioned without being recommended are present but not advancing.

AI systems build those shortlists from available public evidence: clinical credibility signals, structured pricing information, review data, comparison content, and entity clarity. A brand that appears in 40% of AI responses but lacks the evidence architecture to earn a rank is not competing effectively in AI-driven discovery.

This shifts the strategic question for brands in the category. The relevant metric is no longer how often a brand appears. It is whether the brand earns a ranked position when it does appear, and on which platforms that ranking holds.

Directional Category Leaders

1. Nurx

Nurx leads the category with a monthly AI Authority Value of $2.80M and a 15% captured share of the total modeled opportunity. Its valid recommendation coverage of 4.7% is not the highest in absolute terms, but its average recommended rank of 1.83 is the strongest in the market. On ChatGPT and Perplexity, where recommendation rank carries the most commercial weight, Nurx achieves top-1 rates of 5.9% and 8.2% respectively. The brand appears in 19.2% of all observations and converts those appearances into ranked recommendations at a higher rate than any competitor.

The public interpretation: Nurx has built the strongest AI shortlist position in the category, particularly on the platforms where buyers are most likely to act on a first-ranked recommendation.

2. Everlywell

Everlywell is the most visible brand in the category by a significant margin, appearing in 62.9% of all AI responses. Its monthly AI Authority Value of $936.5K places it second overall, supported by a top-1 recommendation rate of 8.6% and an average rank of 1.43 where it is recommended. However, valid recommendation coverage of 13.7% does not match the scale of its visibility. On Gemini and Google AI Mode, Everlywell performs well. On ChatGPT, recommendation coverage drops to 11.2%. The brand is broadly recognized by AI systems but is not consistently advanced into shortlist positions across all platforms.

The public interpretation: Everlywell has exceptional AI presence but leaves meaningful opportunity unrealized by not converting more of that visibility into ranked recommendations.

3. LetsGetChecked

LetsGetChecked holds third position with a monthly AI Authority Value of $337.5K. It appears in 49.6% of responses and achieves a valid recommendation coverage of 10.9%, with a top-3 rate of 8.5% and an average rank of 2.08. Performance is strongest on Copilot and Google AI Mode, where recommendation coverage exceeds 14%. The brand indexes particularly well in the pricing and cost cluster, suggesting AI systems associate it with value-oriented buyer intent at the decision stage.

The public interpretation: LetsGetChecked is a consistent mid-tier performer with particular strength in prompts where buyers are close to purchase.

4. myLAB Box

myLAB Box appears in 32.6% of AI responses but captures only 1.1% of the total opportunity, with a monthly AI Authority Value of $208K. Its valid recommendation coverage of 7.3% is moderate, but its average rank of 2.59 is the weakest among brands that receive recommendations. On Copilot, recommendation coverage reaches 11.8%. On ChatGPT, it falls to 3.5%. The brand has broad neutral visibility, meaning it is frequently mentioned in AI responses without being positively recommended.

The public interpretation: myLAB Box has established AI presence but has not translated that presence into reliable shortlist performance across platforms.

5. Labcorp OnDemand

Labcorp OnDemand holds a monthly AI Authority Value of $178.5K with a valid recommendation coverage of 4.3%. It appears in 23.3% of responses and achieves a top-3 rate of 2.9% and an average rank of 2.30. The brand carries a positive sentiment score of 0.24, the highest among tracked competitors, likely reflecting its clinical credibility. Recommendation volume, however, remains low relative to the brand's institutional authority.

The public interpretation: Labcorp OnDemand benefits from strong clinical trust signals but has not converted that credibility into proportional AI recommendation volume.

The Buying Moments That Now Decide the Category

Best At-Home Health Tests

This is the highest-volume discovery cluster, with 492 observations and a modeled opportunity value of $6.48M. Buyers are asking AI for top options without applying specific comparison criteria, making this the most critical first-impression moment in the category. Nurx leads with an AI Authority Value of $1.22M in this cluster, followed by Everlywell at $380K. Brands that appear here without earning recommendations, including STDcheck.com and QuestDirect, miss the moment when buyer intent is forming and shortlist positions are being set.

At-Home Health Test Comparisons

With 419 observations and a $7.71M modeled opportunity, this cluster captures buyers who are actively comparing options before committing. A cluster multiplier of 1.25 reflects stronger commercial intent. Nurx leads with $837K in authority value. Everlywell and LetsGetChecked both perform competitively here. myLAB Box appears in 33.2% of responses in this cluster but achieves a recommendation coverage of only 4.5%, confirming that it is being listed rather than preferred when buyers are making direct comparisons.

At-Home Health Test Pricing and Cost

This is the highest-intent cluster in the public dataset, carrying a 1.5 multiplier and a $4.48M total opportunity across 425 observations. Buyers here are close to purchase and seeking cost clarity. Nurx leads with $745K in authority value. LetsGetChecked performs its strongest across all clusters here at $174K, reinforcing its association with value-oriented positioning. Brands without transparent and AI-retrievable pricing, including Priority STD Testing and Health Testing Centers, are largely absent from recommendations at this decisive moment.

Why Recommendation Power Is Concentrating

AI systems are not distributing recommendations evenly across this category. They are concentrating around brands that offer clear, consistent, and retrievable signals: structured service descriptions, visible clinical or regulatory credibility, review signals, and transparent pricing. Nurx benefits from a combination of direct-to-consumer positioning and clinical clarity that AI systems can compare and rank reliably. Everlywell's broad presence reflects strong content coverage, but gaps in structured recommendation signals limit how often that presence converts to a ranked outcome.

Public evidence architecture shapes this dynamic. Brands that appear in comparison articles, consumer review platforms, official health content, and structured pricing pages are more likely to earn both mentions and recommendations. Brands that appear primarily in neutral references or brand-owned content without third-party confirmation are more likely to be listed without being advanced.

The concentration effect compounds over time. As Nurx receives more ranked recommendations, its citation footprint in AI training and retrieval sources grows, increasing the probability of future recommendations. Lower-ranked brands face a widening gap that requires deliberate structural intervention, not just increased content production.

The Category's Most Visible Warning Sign

STDcheck.com is the clearest example of the visibility-without-recommendation failure in this dataset. The brand appears in 6.2% of all AI responses and reaches 21.4% appearance rates on Gemini specifically. Yet across all six platforms and all tracked clusters, STDcheck.com receives zero ranked recommendations. Its positive visibility rate is 0.5%. For a brand whose name directly signals category relevance, this represents a fundamental disconnect between recognition and trust.

AI systems are aware of STDcheck.com. They are not recommending it. That distinction is the difference between being in the room and being on the shortlist, and in AI-driven discovery, only the shortlist drives commercial outcomes.

What This Means for the Category

The at-home STD testing market is experiencing shortlist compression. Nurx and Everlywell together account for a disproportionate share of recommendation credit, while eight other tracked brands compete for the remainder. This concentration is likely to intensify as citation patterns in AI retrieval sources become more entrenched around the leading brands.

Competitor displacement is already structurally underway. Brands in the lower recommendation tiers are not simply underperforming on a relative basis. They are being functionally excluded from the discovery moments that drive buyer decisions. A brand that does not appear in a ranked AI recommendation during the consideration or evaluation stage may not appear at all in the buyer's awareness.

Trust-source dependency is reshaping competitive advantage in ways that traditional marketing investment does not address. Clinical credibility alone, as Labcorp OnDemand demonstrates, does not produce recommendation volume without the supporting content and entity architecture that AI systems use to rank and compare.

For brands that underperform in this dataset, the recovery path requires stronger entity clarity, better source coverage in third-party and comparison contexts, and content strategies built around how AI systems retrieve and evaluate options rather than how search engines index pages.

What This Public Benchmark Does Not Include

- Full cluster dataset (10 total clusters; 3 are shown here)

- Prompt-level response tables

- Citation-source failure maps

- Platform-by-platform recovery priorities

- Entity and schema diagnostics

- Source-layer gap analysis

- Company-specific content recommendations

- Exact competitor threat profiles

- Full paid opportunity model

This page shows the market shape. The paid report shows the repair map.

Methodology and Disclaimers

1. Market studied: At-home STD test services and direct-to-consumer health testing brands.

2. Brands and entities included: Everlywell, Health Testing Centers, Labcorp OnDemand, LetsGetChecked, myLAB Box, Nurx, PlushCare, Priority STD Testing, QuestDirect, STDcheck.com.

3. Data collection window: June 2026.

4. AI platforms tracked: ChatGPT, Copilot, Gemini, Google AI Mode, Google AI Overviews, Perplexity.

5. Observations analyzed: 1,336 observations across three public high-intent clusters.

6. Prompt categories: Discovery prompts (Best At-Home Health Tests), evaluation prompts (At-Home Health Test Comparisons), and decision-stage prompts (At-Home Health Test Pricing and Cost).

7. Definition of a mention: A brand appeared in an AI-generated response, regardless of sentiment or rank.

8. Definition of a valid recommendation: A positive, shortlist-quality or ranked recommendation that earns recommendation credit. Visibility and recommendation credit are treated as distinct metrics throughout this report.

9. Metrics used: Valid recommendation coverage, top-3 rate, top-1 rate, average recommended rank, net sentiment score, monthly AI Authority Value, monthly AI Recommendation Value, and captured share of total modeled opportunity.

10. Limitations: This is a point-in-time benchmark. AI outputs change as retrieval sources, model updates, and citation patterns evolve. Modeled opportunity values are estimates and do not represent realized revenue. This benchmark is not a full audit or a complete market census.

Ready to See the Full Picture?

For a company-specific Authority Index report, the deeper analysis would show which prompts each company wins or loses, which AI platforms are under-recognizing the brand, which source layers are shaping recommendations, and what changes may improve AI shortlist eligibility.